FDA proposes withdrawing Tavneos approval in the US
FDA proposed withdrawing Tavneos' US approval due to safety concerns and trial data issues, citing severe liver injuries and insufficient effectiveness evidence. Amgen, which acquired ChemoCentryx, disputes the FDA's claims, arguing that data reassessment corrected errors and real-world data supports the drug's benefits. The FDA may hold a public hearing before making a final decision.
How this was made
The 30-second read
Why it matters
Regulatory action threatens revenue from a rare‑disease drug and may trigger a write‑down for Amgen's recent acquisition.
Market read
Immediate negative impact on CCXI and AMGN; broader biotech risk sentiment.
What to watch
Potential for alternative indications of Tavneos or other pipeline assets to mitigate impact.
Background
The FDA's April 2026 proposal to withdraw Tavneos follows reports of severe liver injuries and alleged trial protocol violations.
Ticker impact
Amgen, which acquired ChemoCentryx, faces possible loss of a $4 bn acquisition target's key drug.
likely decline as investors assess earnings impact
Amgen's recent acquisition is now at risk, which could affect its pipeline and financial outlook.
Market effects
Biotech sector may see broader risk aversion as FDA actions highlight regulatory scrutiny.
U.S. biotech stocks could face short‑term pressure.
Potential ripple to global pharma investors tracking FDA decisions.
Counterpoint
If Amgen successfully challenges the withdrawal, the stock could rebound.
Key entities
- companyChemoCentryx
Biotech developer of Tavneos, now facing FDA withdrawal.
- companyAmgen
Parent company of ChemoCentryx, acquired for ~$4 bn.
- regulatorFDA
U.S. agency proposing the drug's withdrawal.
